In a 7-year follow-up, compared to non-diabetic patients, patients with type 2 diabetes experienced significantly more average peri-implant bone loss (Al Zahrani and Al Mutairi, 2018), while the implant success rate in patients treated with insulin and other interventions and controlled blood sugar levels was comparable to that of ordinary people. The gene discussed is INS; the disease is type 2 diabetes mellitus.